Document is current
Any future updates will be listed below
-
Authors
Suzuki, Takefumi
Susa, Koichiro
Kikuchi, Hiroaki
Nakano, Yuta
Yanagi, Tomoki
Hara, Yu
Fujiki, Tamami
Ando, Fumiaki
Mandai, Shintaro
Mori, Yutaro
Mori, Takayasu
Iwasa, Hiroaki
Hata, Yutaka
Uchida, Shinichi
Sohara, Eisei
-
Funding
Funding for this research was provided by:
Japan Agency for Medical Research and Development (JP21ek0310018, 24ek0310023h0001, 19ek0109304h0002, 21ek0109554h0001)
Japan Society for the Promotion of Science (19K17699, 23K19610, 19H01049, 19H03672)
Uehara Memorial Foundation
Takeda Science Foundation
- License Information
-
More Information
Article History
Received: 4 June 2025
Accepted: 14 August 2025
First Online: 19 September 2025
Declarations
:
: Human iPSC 1231A3 deposited at the RIKEN BRC was established by Kyoto University from ePBMC® purchased from Cellular Technology Limited (). The original source has confirmed that ethical approval was obtained initially for collection of human cells in full compliance with HIPAA guidelines, and that the donor had signed informed consent. (Sci Rep. 2014 Jan 8:4:3594. PMID: 24399248). This study was approved by the research ethics committee of Institute of Science Tokyo. Approved project title: Generation and analysis of iPS cells of wild type and inherited cystic kidney disease. Approval number: G2018-005. Approval date: 29 September 2020.
: Not applicable.
: The authors declare no competing interests.
